Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 156 of the 157 references it cites were found in a registry or an index.

Impaired dopamine release in Parkinson’s disease

Open access
Cramb, Kaitlyn M L, Beccano-Kelly, Dayne, Cragg, Stephanie J, Wade-Martins, Richard · 2023 · Brain

Abstract

Parkinson’s disease is the second most common neurodegenerative disease and yet the early pathophysiological events of the condition and sequences of dysfunction remain unclear. The loss of dopaminergic neurons and reduced levels of striatal dopamine are descriptions used interchangeably as underlying the motor deficits in Parkinson’s disease. However, decades of research suggest that dopamine release deficits in Parkinson’s disease do not occur only after cell death, but that there is dysfunction or dysregulation of axonal dopamine release before cell loss. Here we review the evidence for dopamine release deficits prior to neurodegeneration in Parkinson’s disease, drawn from a large and emerging range of Parkinson’s disease models, and the mechanisms by which these release deficits occur. The evidence indicates that impaired dopamine release can result from disruption to a diverse range of Parkinson’s disease-associated genetic and molecular disturbances, and can be considered as a potential pathophysiological hallmark of Parkinson’s disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/awad064

Cites

156 of 156 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 DA release in the nigrostriatal pathway and simplified working hypothesis for Parkinson’s disease progression. DAN cell bodies reside in the SNpc and project extensive axonal arbourizations to the dorsal striatum where they release DA (left). DA release occurs at active axonal varicosities and acts on D1 and D2 receptors on striatal cells (middle). In Parkinson’s disease, the nigrostriatal pathway is most affected and results in progressively decreased DA release (top right), and eventually axon degeneration and cell death (bottom right) impairing downstream signalling and movement modulation. Cellular dysfunction and altered striatal DA release precede cell death. DA release is modulated by neighbouring cell types including astrocytes, which can contribute to DA release defects observed in Parkinson’s disease models, such as by downregulation of GAT. Radiotracers used to image dopaminergic dysfunction in living human brains include 11C-raclopride that binds available D2 receptors and 18F-DOPA, which is a substrate for DOPA decarboxylase (DDC).
Figure 1 DA release in the nigrostriatal pathway and simplified working hypothesis for Parkinson’s disease progression. DAN cell bodies reside in the SNpc and project extensive axonal arbourizations to the dorsal striatum where they release DA (left). DA release occurs at active axonal varicosities and acts on D1 and D2 receptors on striatal cells (middle). In Parkinson’s disease, the nigrostriatal pathway is most affected and results in progressively decreased DA release (top right), and eventually axon degeneration and cell death (bottom right) impairing downstream signalling and movement modulation. Cellular dysfunction and altered striatal DA release precede cell death. DA release is modulated by neighbouring cell types including astrocytes, which can contribute to DA release defects observed in Parkinson’s disease models, such as by downregulation of GAT. Radiotracers used to image dopaminergic dysfunction in living human brains include 11C-raclopride that binds available D2 receptors and 18F-DOPA, which is a substrate for DOPA decarboxylase (DDC).CC BY · PubMed Central
Figure 2 Cell-autonomous presynaptic mechanisms of dysfunctional DA release in Parkinson’s disease models. Defects in many different aspects of DA handling can lead to defective DA release. These include: defective exocytosis machinery including SNARE-complex formation and fusion (1); impaired DA synthesis, its loading into SVs via VMAT2 and trafficking to release sites (2); damage to the vesicular pool (3); recycling of DA following release, including recycling of SV through endocytosis and reuptake via DAT (4); and protein aggregation (5).
Figure 2 Cell-autonomous presynaptic mechanisms of dysfunctional DA release in Parkinson’s disease models. Defects in many different aspects of DA handling can lead to defective DA release. These include: defective exocytosis machinery including SNARE-complex formation and fusion (1); impaired DA synthesis, its loading into SVs via VMAT2 and trafficking to release sites (2); damage to the vesicular pool (3); recycling of DA following release, including recycling of SV through endocytosis and reuptake via DAT (4); and protein aggregation (5).CC BY · PubMed Central
Figure 3 Overview of multifactorial cellular dysfunction converging on defective DA release. Dysfunction in several different cellular processes result in dysfunctional DA release in Parkinson’s disease models. Prolonged dysfunction, probably in combination with cell death, leads to reduced striatal DA that, once a threshold is reached, leads to the hallmark motor symptoms of Parkinson’s disease. The level of this threshold is modulated by compensatory factors.
Figure 3 Overview of multifactorial cellular dysfunction converging on defective DA release. Dysfunction in several different cellular processes result in dysfunctional DA release in Parkinson’s disease models. Prolonged dysfunction, probably in combination with cell death, leads to reduced striatal DA that, once a threshold is reached, leads to the hallmark motor symptoms of Parkinson’s disease. The level of this threshold is modulated by compensatory factors.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 157 references

Cited by

See all 228

Metadata

Authors
Cramb, K. M. L., Beccano-Kelly, D., Cragg, S. J., & Wade-Martins, R.
Affiliations
  • University of Oxford (GB)
  • Oxford Parkinson’s Disease Centre and Department of Physiology, Anatomy and Genetics, University of Oxford , Oxford, OX1 3QU , UK
Corresponding author
Cragg, Stephanie J
Venue
Brain
Published
2023-03-02
Volume
146
Issue
8
Pages
3117-3132
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W4323036321
Cited by
207
References
157
Citations by year
2026: 63 · 2025: 75 · 2024: 60 · 2023: 8
FWCI
8.38
Type
journal article
Language
en
Open access
Locations
  • Brain (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Monument Trust Discovery Award from Parkinson’s UK (J-1403)
  • MJFF (ASAP-020370)
  • Natural Sciences and Engineering Research Council of Canada (PGSD3-517039-2018)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
Parkinson's disease, dopamine release, dopaminergic neurons, striatal dopamine, neurodegeneration, Parkinson's disease model, pathophysiology
MeSH terms
Dopamine, Humans, Parkinson Disease, Neurodegenerative Diseases, Dopaminergic Neurons

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impaired dopamine release in Parkinson’s disease. https://app.cochat.ai/papers/10.1093/brain/awad064
The paper
Cramb, K. M. L., Beccano-Kelly, D., Cragg, S. J., & Wade-Martins, R. (2023). Impaired dopamine release in Parkinson’s disease. Brain. https://doi.org/10.1093/brain/awad064

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.